Literature DB >> 8167132

Preoperative predictors of survival in patients with Thoratec ventricular assist devices as a bridge to heart transplantation. Thoratec Ventricular Assist Device Principal Investigators.

D J Farrar1.   

Abstract

Approximately two-thirds of patients implanted with ventricular assist devices recover sufficiently to requalify for heart transplantation, and the other one-third die of complications that are often secondary to delayed ventricular assist device implantation and subsequent end-organ failure. To determine whether any preoperative predictors of survival exist, univariate statistics and multivariate stepwise logistic regression analysis were performed on pre-ventricular assist device demographics, hemodynamics, and blood chemistry in 186 patients receiving Thoratec ventricular assist devices (Thoratec Laboratories Corp., Berkeley, Calif.) while awaiting transplantation. The duration of circulatory support averaged 19.6 days (maximum, 226 days). One hundred thirty-seven patients (74%) received biventricular support, 47 received isolated left ventricular assist devices, and two received right ventricular assist devices. The average blood flow was 5.0 +/- 0.9 L/min. One hundred eighteen patients (63%) ultimately received heart transplants, of whom 96 patients were discharged. Age, gender, weight, and diagnosis were not related to survival, nor were preoperative cardiac index, pulmonary capillary wedge pressure, intraaortic balloon pumps, or cardiac arrests. Pre-ventricular assist device creatinine levels (p = 0.24) and total bilirubin levels (p = 0.09) were not significant, but blood urea nitrogen level (p = 0.02) and previous operations (p = 0.05) were related to survival, using univariate techniques. Patients with cardiac operations more than 30 days previously had the lowest survival-to-transplantation (39%) compared with patients with no previous operations (67%) or operations within the previous 30 days (61%). Blood urea nitrogen level was the only parameter found to be significant (p = 0.016) in a multivariate model.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8167132

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  4 in total

1.  Thoratec paracorporeal biventricular assist device therapy: the Freiburg experience.

Authors:  Kerstin Brehm; Claudia Heilmann; Matthias Siepe; Christoph Benk; Friedhelm Beyersdorf; Christian Schlensak
Journal:  Eur J Cardiothorac Surg       Date:  2012-01       Impact factor: 4.191

2.  The use of extracorporeal membrane oxygenation in patients with therapy refractory cardiogenic shock as a bridge to implantable left ventricular assist device and perioperative right heart support.

Authors:  Mirela Scherer; Anton Moritz; Sven Martens
Journal:  J Artif Organs       Date:  2009-09-19       Impact factor: 1.731

3.  Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.

Authors:  Tomoko S Kato; Shuichi Kitada; Jonathan Yang; Christina Wu; Hiroo Takayama; Yoshifumi Naka; Maryjane Farr; Donna M Mancini; P Christian Schulze
Journal:  Am J Cardiol       Date:  2013-07-25       Impact factor: 2.778

4.  Percutaneous ventricular assist device placement during active cardiopulmonary resuscitation for severe refractory cardiogenic shock after acute myocardial infarction.

Authors:  Gary M Idelchik; Pranav Loyalka; Biswajit Kar
Journal:  Tex Heart Inst J       Date:  2007
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.